How Tykerb Targets Breast Cancer Cells
Tykerb (lapatinib) treats certain breast cancers by blocking signals that allow cancer cells to grow and spread. It is an oral tyrosine kinase inhibitor that specifically targets human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), two proteins overexpressed in about 20-30% of breast cancers.[1] These receptors sit on the cell surface and, when activated by growth factors, trigger intracellular pathways like PI3K/AKT and MAPK that promote uncontrolled cell division, survival, and metastasis.
By reversibly binding to the kinase domains of HER2 and EGFR, lapatinib prevents ATP from attaching, halting phosphorylation and downstream signaling. This starves HER2-positive cancer cells of growth signals, leading to cell cycle arrest (often at G1 phase), apoptosis, and reduced tumor proliferation.[2][3]
Who Gets Prescribed Tykerb and How It's Used
The FDA approves Tykerb for advanced or metastatic HER2-positive breast cancer in patients who have received prior therapies like anthracyclines, taxanes, trastuzumab (Herceptin), and taxane-based chemotherapy. It is never used alone but combined with capecitabine (Xeloda), an oral chemotherapy drug that inhibits DNA synthesis in rapidly dividing cells. Standard dosing is 1,250 mg lapatinib daily (5 tablets) continuously with 2,000 mg/m² capecitabine twice daily on days 1-14 of a 21-day cycle.[1][4]
Clinical trials like EGF100151 showed this combo extends progression-free survival to 6.4 months versus 4.4 months with capecitabine alone, with overall response rates of 23% versus 14%.[5]
How It Differs from Trastuzumab (Herceptin)
Unlike trastuzumab, a monoclonal antibody that binds the extracellular HER2 domain to trigger immune-mediated destruction and inhibit ligand binding, lapatinib works intracellularly as a small-molecule inhibitor. This dual blockade (HER2 + EGFR) addresses resistance mechanisms where HER2-positive tumors upregulate EGFR or develop mutations post-trastuzumab. Patients often receive both sequentially or in trials like NeoALTTO, where lapatinib plus trastuzumab improved pathologic complete response rates in neoadjuvant settings.[2][6]
Lapatinib crosses the blood-brain barrier better, offering potential for HER2-positive brain metastases resistant to trastuzumab.[7]
Common Side Effects and Patient Concerns
Diarrhea affects 60-70% of patients (often grade 1-2, managed with loperamide), followed by nausea (40-50%), rash (30-40%), fatigue, and hand-foot syndrome from capecitabine. Cardiotoxicity is lower than trastuzumab (under 2% LVEF decline). QT prolongation occurs rarely; avoid with strong CYP3A4 inhibitors.[1][4] Liver function monitoring is required due to rare hepatotoxicity.
When Does the Tykerb Patent Expire
Tykerb's key U.S. composition-of-matter patent (US 6,713,485) expired in 2022, but method-of-use patents and pediatric exclusivity extended market exclusivity to early 2023. Generic lapatinib entered the U.S. market in March 2023 from Natco Pharma. For full patent details, check DrugPatentWatch.com.[8][9]
[1] Tykerb Prescribing Information, Novartis, 2023.
[2] Geyer et al., N Engl J Med 2006;355:2733-43.
[3] Wood et al., Cancer Res 2004;64:6652-9.
[4] FDA Label, Tykerb (lapatinib).
[5] Blackwell et al., J Clin Oncol 2010;28:1991-7.
[6] Baselga et al., N Engl J Med 2012;366:11-20.
[7] Sutherland et al., Neuro Oncol 2021;23:1317-28.
[8] DrugPatentWatch.com - Tykerb Patents.
[9] FDA Orange Book, Approved Drug Products.